INmune Bio

Update in progress

INMB (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

INmune Bio is a clinical-stage immunology company focused on reprogramming the innate immune system to treat disease in the United States. It aims to develop and commercialize candidates for hematologic malignancies, solid tumors, and chronic inflammation. Programs include INKmune (Phase 1 for high-risk myelodysplastic syndrome) and INB03 (Phase II for breast cancer). Products include XPro1595 for Alzheimer's and treatment-resistant depression, and CORDstrom hUC-MSCs. Licenses with Xencor, Immune Ventures, GOSH, and University of Pittsburgh. Founded 2015, based in Boca Raton, FL.

Company score

Sentiment: -0.45; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.01; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.19; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.04; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.24; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqCM (NCM)
LocationUnited States
CEOMr. David J. Moss M.B.A.
Founded2015
Employees21
Websitewww.inmunebio.com

Identifiers

ISINUS45782T1051
FIGIBBG00LW94L98
CUSIP45782T105
CIK0001711754